Compare Starbucks Corp (SBUX) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs 10X Genomics Inc — how do they compare? Starbucks Corp trades at $91.9 (market cap $106.26B), while 10X Genomics Inc trades at $83.55 (market cap $10.07B). The key difference: Starbucks Corp is far larger — about 10.6× 10X Genomics Inc's market cap, and Starbucks Corp pays a 2.7% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Starbucks Corp for 190 Days and 10X Genomics Inc for 92 Days on average.
| SBUX | TXG | |
|---|---|---|
Market Cap | $106.26B | $10.07B |
Volume | 30,248,434 | 5,657,286 |
Sector | Consumer Cyclical | Health |
52-Week High | $108.55 | $97.74 |
52-Week Low | $78.46 | $11.48 |
Typical Hold Time | 190 Days | 92 Days |
Enterprise Value | $125.08B | $9.59B |
Dividend Yield | 2.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $93.58, down 2.63% on the day, as the company navigates a strategic restructuring with 250 North American store closures. The stock shows mixed technical signals with bearish moving averages but neutral oscillators. Fundamentally, SBUX maintains stable revenue growth but faces margin compression, with net income declining to $1.86B in 2025. Analyst consensus remains positive with a $115.50 price target, though recent news highlights operational challenges and geopolitical tensions.
The outlook for SBUX balances near-term headwinds from restructuring costs against long-term growth potential in international markets. Investment opportunities include strong brand equity and dividend consistency, while risks involve labor relations, Chinese market exposure, and execution of the store optimization strategy. The current valuation at 53.88x P/E requires sustained earnings recovery to justify upside.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
